A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
An HIV antibody achieves potency and breadth by binding simultaneously to two conserved glycans on the viral envelope protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
EMAN2: An extensible image processing suite for electron microscopy
Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.05.009 · Cited by 2,994
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
EMAN: Semiautomated Software for High-Resolution Single-Particle Reconstructions
Ludtke, S. J., Baldwin, P. R., & Chiu, W. (1999) · Journal of Structural Biology · doi:10.1006/jsbi.1999.4174 · Cited by 2,391
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citation
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by specific antibodies, such as that seen on the surface of the HIV virion (507) (508) (509) 594) .”
BackgroundFUBAR: A Fast, Unconstrained Bayesian AppRoximation for Inferring Selection
Murrell, B., Moola, S., Mabona, A., Weighill, T., Sheward, D., Kosakovsky Pond, S. L., & Scheffler, K. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst030 · Cited by 1,358
“Several potent and broadly crossneutralizing HIV antibodies (PG9/ PG16-like and PGT128-like antibodies) are dependent on both a peptide and a glycan component for binding (McLellan et al. 2011; Pejchal et al. 2011), providing a precedent for this mode of recognition.”
BackgroundSanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
“664 gp140 trimers have already been already useful for structure-based studies aimed at defining bNAbEnv interactions [25,26,27], as were the corresponding trimers based on the KNH1144 env gene [46,48,60].”
BackgroundMethodSelf-citationStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationCrystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
Julien, J.-P., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., et al. (2013) · Science · doi:10.1126/science.1245625 · Cited by 797
“Whereas the PGT128 heavy chain predominantly interacts with the gp120 V3 base, PGT122 recognizes this region mainly through its light chain.”
BackgroundInfluentialSelf-citationRational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770
Self-citationDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Self-citationCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Lyumkis, D., Julien, J.-P., de Val, N., Cupo, A., Potter, C. S., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B., et al. (2013) · Science · doi:10.1126/science.1245627 · Cited by 669
Self-citationBroadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
Burton, D. R., & Hangartner, L. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055515 · Cited by 583
“The contact residues for PG9 are blue (99); PGT122 dark purple (22); PGT128 light purple (96); PGT135 medium purple (136); VRC01 green (88); b12 olive green, from alanine scan (160); PGT151 dark red (98); 8ANC195 medium red (86, 87); and 35O22 light red (24).”
BackgroundSelf-citationPeptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies
Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J. F., Halper-Stromberg, A., Gnanapragasam, P. N. P., Spencer, D. I. R., Seaman, M. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217207109 · Cited by 550
“Black dashed and solid lines show positive (10-188) and negative (mG053) controls, respectively.”
BackgroundMethodResultInfluentialSelf-citationMultivalent glycoconjugates as anti-pathogenic agents
Bernardi, A., Jiménez-Barbero, J., Casnati, A., De Castro, C., Darbre, T., Fieschi, F., Finne, J., Funken, H., Jaeger, K.-E., Lahmann, M., et al. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35408j · Cited by 537
Klein, F., Diskin, R., Scheid, J. F., Gaebler, C., Mouquet, H., Georgiev, I. S., Pancera, M., Zhou, T., Incesu, R.-B., Fu, B. Z., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.018 · Cited by 537
“Moreover the ligand-bound structure of PGT128 (Pejchal et al., 2011) shows that the carbohydrate attached to Asnl21gp120 interacts with residues within the C” β-strand of the antibody heavy chain (Trp56, Thr57, His59 and Lys64).”
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014) · Cell · doi:10.1016/j.cell.2014.08.023 · Cited by 493
“These included the anti-CD4 binding site (CD4bs) monoclonal antibodies (mAbs) 3BNC117 (Scheid et al., 2011), 3BNC60 (Scheid et al., 2011), and 1-74 (Scheid et al., 2009); 3BC176, a mAb recognizing a conformational V3/CD4i epitope (Klein et al., 2012a); PG16, an anti-V1/2 mAb (Walker et al., 2009); and the anti-V3 mAbs…”
B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2197 · Cited by 486
Cross-neutralization of influenza A viruses mediated by a single antibody loop
Ekiert, D. C., Kashyap, A. K., Steel, J., Rubrum, A., Bhabha, G., Khayat, R., Lee, J. H., Dillon, M. A., O’Neil, R. E., Faynboym, A. M., et al. (2012) · Nature · doi:10.1038/nature11414 · Cited by 481
“The experiments comprised five steps: (1) baseline acquisition (60 s); (2) HA loading onto sensor (300–600 s); (3) second baseline acquisition (180–200 s); (4) association of C05 for the measurement of kon (180 s); and (5) dissociation of C05 for themeasurement of koff (180 s).”
Self-citationExploitation of glycosylation in enveloped virus pathobiology
Watanabe, Y., Bowden, T. A., Wilson, I. A., & Crispin, M. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.05.012 · Cited by 482
Self-citationHIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
“Pancera M, et al. N332-directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.”
BackgroundInfluentialBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
“A crystal structure of PGT128 bound to its ligand shows that it contacts the Cterminal end of the V3 loop, Man8/9 and Man5GlcNAc2 at positions N332 and N301, respectively (61).”
BackgroundHuman Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
“Thus, mAbs PGT128, PGT135, and 2G12 all recognize distinct but overlapping epitopes, where the main overlap is the involvement of glycan at N332.”
InfluentialEmerging principles for the therapeutic exploitation of glycosylation
Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., & Dwek, R. A. (2014) · Science · doi:10.1126/science.1235681 · Cited by 447
“The position of the glycan at N322 is shown together with the crystal structures of the Fabs of PGT128 (red), PGT135 (gray), and 2G12 (blue) (52, 54, 55).”
BackgroundSelf-citationBurton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1225416 · Cited by 415
Self-citationTrimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G
Stewart-Jones, G. B. E., Soto, C., Lemmin, T., Chuang, G.-Y., Druz, A., Kong, R., Thomas, P. V., Wagh, K., Zhou, T., Behrens, A.-J., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.010 · Cited by 404
“, 2015) or from glycans bound by antibody (Kong et al., 2013; McLellan et al., 2011; Pejchal et al., 2011), which interrupt branch interactions that provide the dominant form of glycan-glycan contact (Figure 3C).”
InfluentialSelf-citationAntibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Self-citationAnalysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition
Grant, O. C., Montgomery, D., Ito, K., & Woods, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-71748-7 · Cited by 372
A Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 375
“However, new data bring this requirement into question and may offer new strategies for vaccine targeting either of the glycan shield or of penetrating the shield via a mixed protein-glycan immunogen (Pejchal et al., 2011; Walker et al., 2011a).”
Self-citationFalkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C., Ramirez, A., Derking, R., van Gils, M. J., Liang, C.-H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.009 · Cited by 359
“The results for PGT128 and 2G12 were taken from earlier experiments performed with different versions of the microarrays, as described (Pejchal et al., 2011).”
Self-citationDo Kwon, Y., Pancera, M., Acharya, P., Georgiev, I. S., Crooks, E. T., Gorman, J., Joyce, M. G., Guttman, M., Ma, X., Narpala, S., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3051 · Cited by 345
Blattner, C., Lee, J. H., Sliepen, K., Derking, R., Falkowska, E., de la Peña, A. T., Cupo, A., Julien, J.-P., van Gils, M., Lee, P. S., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.008 · Cited by 332
“A long HCDR3 loop is a feature common to most other glycan-binding bnAbs (Julien et al., 2013c; Kong et al., 2013; McLellan et al., 2011; Pejchal et al., 2011).”
BackgroundMethodInfluentialSelf-citationSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
Kong, L., Lee, J. H., Doores, K. J., Murin, C. D., Julien, J.-P., McBride, R., Liu, Y., Marozsan, A., Cupo, A., Klasse, P.-J., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2594 · Cited by 337
Self-citationBroadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
Zhou, T., Lynch, R. M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N. A., Joyce, M. G., Lingwood, D., Soto, C., Bailer, R. T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.007 · Cited by 310
“…2012; Ofek et al., 2004), or the glycan-V3 supersite on gp120, where longitudinal approach angles ranged from 15 to 95 degrees among four representative antibodies (PGT122, PGT128, PGT135 and 2G12) (Calarese et al., 2003; Julien et al., 2013; Kong et al., 2013; Pejchal et al., 2011)(Figure S3).”
Self-citationHIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
Kwong, P. D., & Mascola, J. R. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.029 · Cited by 304
High-sensitivity Analytical Approaches for the Structural Characterization of Glycoproteins
Alley, W. R., Mann, B. F., & Novotny, M. V. (2013) · Chemical Reviews · doi:10.1021/cr3003714 · Cited by 310
Julien, J.-P., Sok, D., Khayat, R., Lee, J. H., Doores, K. J., Walker, L. M., Ramos, A., Diwanji, D. C., Pejchal, R., Cupo, A., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003342 · Cited by 293
“Our model predicts that the N301 and N332 glycans might be accommodated by elements of the light chain CDRs and at the interface between light chain CDRs and HCDR3, respectively (Fig.”
BackgroundResultInfluentialSelf-citationRudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02213-14 · Cited by 282
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape
Moore, P. L., Gray, E. S., Wibmer, C. K., Bhiman, J. N., Nonyane, M., Sheward, D. J., Hermanus, T., Bajimaya, S., Tumba, N. L., Abrahams, M.-R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2985 · Cited by 285
Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
Bonsignori, M., Kreider, E. F., Fera, D., Meyerhoff, R. R., Bradley, T., Wiehe, K., Alam, S. M., Aussedat, B., Walkowicz, W. E., Hwang, K.-K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7514 · Cited by 270
Xu, K., Acharya, P., Kong, R., Cheng, C., Chuang, G.-Y., Liu, K., Louder, M. K., O’Dell, S., Rawi, R., Sastry, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0042-6 · Cited by 283
Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16
Pancera, M., Shahzad-ul-Hussan, S., Doria-Rose, N. A., McLellan, J. S., Bailer, R. T., Dai, K., Loesgen, S., Louder, M. K., Staupe, R. P., Yang, Y., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2600 · Cited by 270
Self-citationNabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Self-citationBehrens, A.-J., Vasiljevic, S., Pritchard, L. K., Harvey, D. J., Andev, R. S., Krumm, S. A., Struwe, W. B., Cupo, A., Kumar, A., Zitzmann, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.058 · Cited by 250
“The N332 glycan, a key component of the so-called ‘‘supersite’’ of immune vulnerability (Kong et al., 2013; Mouquet et al., 2012; Pejchal et al., 2011; Walker et al., 2011), resides at the heart of this site.”
BackgroundInfluentialSelf-citationThe HIV ‐1 envelope glycoprotein structure: nailing down a moving target
Ward, A. B., & Wilson, I. A. (2017) · Immunological Reviews · doi:10.1111/imr.12507 · Cited by 246
Self-citationAsymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9
Julien, J.-P., Lee, J. H., Cupo, A., Murin, C. D., Derking, R., Hoffenberg, S., Caulfield, M. J., King, C. R., Marozsan, A. J., Klasse, P. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217537110 · Cited by 247
“664 gp140 trimer were expressed as recombinant proteins and purified as described (31, 34, 41).”
MethodSelf-citationGeneration of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Lewis, S. M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H. L., Guntas, G., Leaver-Fay, A., Smith, E. M., Ho, C., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2797 · Cited by 234
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
Hudak, J. E., & Bertozzi, C. R. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.010 · Cited by 231
Identification and specificity of broadly neutralizing antibodies against HIV
McCoy, L. E., & Burton, D. R. (2017) · Immunological Reviews · doi:10.1111/imr.12484 · Cited by 213
“22,27,72 By comparing structural information generated for dif - ferent families within this class, it was shown that the N332/GDIR epitope is accessed from a variety of angles by the different bnAbs, which use diverse binding modes, leading to its definition as a super - site of vulnerability.”
Self-citationAntibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike
Scharf, L., Scheid, J. F., Lee, J. H., West, A. P., Chen, C., Gao, H., Gnanapragasam, P. N. P., Mares, R., Seaman, M. S., Ward, A. B., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.001 · Cited by 212
“CDRH3 residues corresponding to 8ANC195HC residues 90–105 (pink) of NIH45-46 (blue; PDB 3U7Y), PG16 (gray; PDB 4DQO), PGT121 (purple; PDB 4FQC), and PGT128 (orange; PDB 3TYG) are shown as Ca traces.”
BackgroundInfluentialSelf-citationMurin, C. D., Wilson, I. A., & Ward, A. B. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0392-y · Cited by 213
Self-citationMenéndez-Arias, L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.01.007 · Cited by 207
Lee, P. S., Ohshima, N., Stanfield, R. L., Yu, W., Iba, Y., Okuno, Y., Kurosawa, Y., & Wilson, I. A. (2014) · Nature Communications · doi:10.1038/ncomms4614 · Cited by 213
Self-citationDelineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization
Georgiev, I. S., Doria-Rose, N. A., Zhou, T., Do Kwon, Y., Staupe, R. P., Moquin, S., Chuang, G.-Y., Louder, M. K., Schmidt, S. D., Altae-Tran, H. R., et al. (2013) · Science · doi:10.1126/science.1233989 · Cited by 212
Gristick, H. B., von Boehmer, L., West Jr, A. P., Schamber, M., Gazumyan, A., Golijanin, J., Seaman, M. S., Fätkenheuer, G., Klein, F., Nussenzweig, M. C., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3291 · Cited by 200
Garces, F., Lee, J. H., de Val, N., Torrents de la Pena, A., Kong, L., Puchades, C., Hua, Y., Stanfield, R. L., Burton, D. R., Moore, J. P., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.11.007 · Cited by 189
“To date, several bnAbs have been isolated from HIV-infected individuals that bind to glycans located in a high-mannose patch centered on the N332 glycan in gp120 and to protein components at the base of the V3 loop (Garces et al., 2014; Kong et al., 2013; Mouquet et al., 2012; Pejchal et al., 2011).”
Self-citationWagh, K., Bhattacharya, T., Williamson, C., Robles, A., Bayne, M., Garrity, J., Rist, M., Rademeyer, C., Yoon, H., Lapedes, A., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005520 · Cited by 191
Self-citationSok, D., Doores, K. J., Briney, B., Le, K. M., Saye-Francisco, K. L., Ramos, A., Kulp, D. W., Julien, J.-P., Menis, S., Wickramasinghe, L., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008104 · Cited by 183
Self-citationRecombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., Diskin, R., Scheid, J. F., Sather, D. N., Burton, D. R., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003106 · Cited by 184
“infected subjects [5–11].”
Self-citationSwearingen, K. E., Lindner, S. E., Shi, L., Shears, M. J., Harupa, A., Hopp, C. S., Vaughan, A. M., Springer, T. A., Moritz, R. L., Kappe, S. H. I., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005606 · Cited by 192
“Their importance has been emphasized recently by broadly neutralizing anti-HIV gp120 antibodies that recognize combinatorial oligosaccharide/protein epitopes [73].”
BackgroundZolla-Pazner, S., deCamp, A. C., Cardozo, T., Karasavvas, N., Gottardo, R., Williams, C., Morris, D. E., Tomaras, G., Rao, M., Billings, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053629 · Cited by 183
Kim, J. H., Excler, J.-L., & Michael, N. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-052912-123749 · Cited by 175
Sok, D., Laserson, U., Laserson, J., Liu, Y., Vigneault, F., Julien, J.-P., Briney, B., Ramos, A., Saye, K. F., Le, K., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003754 · Cited by 184
“The epitope that PGT121 binds to, on the other hand, may be more exposed and may accommodate different antibody binding angles [7,11,37,38].”
BackgroundMethodInfluentialSelf-citationQuantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation
Zhou, T., Doria-Rose, N. A., Cheng, C., Stewart-Jones, G. B. E., Chuang, G.-Y., Chambers, M., Druz, A., Geng, H., McKee, K., Kwon, Y. D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.013 · Cited by 176
“Analysis of known broadly neutralizing HIV-1 antibodies reveals that many of these rare antibodies require recognition of N-linked glycan for high affinity binding (McLellan et al., 2011; Pejchal et al., 2011; Walker et al., 2011; Walker et al., 2009).”
BackgroundNakamura, G., Chai, N., Park, S., Chiang, N., Lin, Z., Chiu, H., Fong, R., Yan, D., Kim, J., Zhang, J., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.06.004 · Cited by 178
“For example, IgG cloning of B cells from HIVinfected patients with broadly neutralizing serum has yielded some very potent antibodies (Wu et al., 2010; Pejchal et al., 2011; Walker et al., 2011).”
BackgroundStructural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies
Garces, F., Sok, D., Kong, L., McBride, R., Kim, H. J., Saye-Francisco, K. F., Julien, J.-P., Hua, Y., Cupo, A., Moore, J. P., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.009 · Cited by 178
“These bnAbs include antibody families from different germline lineages such as PGT121–123/PGT133– 134/10-1074, PGT125–128/PGT130–131, and PGT135–137 (Julien et al., 2013c; Kong et al., 2013; Mouquet et al., 2012; Pejchal et al., 2011;Walker et al., 2011).”
InfluentialSelf-citationCATNAP: a tool to compile, analyze and tally neutralizing antibody panels
Yoon, H., Macke, J., West, A. P., Foley, B., Bjorkman, P. J., Korber, B., & Yusim, K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv404 · Cited by 168
Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development
Bonsignori, M., Liao, H., Gao, F., Williams, W. B., Alam, S. M., Montefiori, D. C., & Haynes, B. F. (2017) · Immunological Reviews · doi:10.1111/imr.12509 · Cited by 168
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Nimmerjahn, F., Gordan, S., & Lux, A. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.005 · Cited by 172
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Bricault, C. A., Yusim, K., Seaman, M. S., Yoon, H., Theiler, J., Giorgi, E. E., Wagh, K., Theiler, M., Hraber, P., Macke, J. P., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2018.12.001 · Cited by 178
“Fourteen V3 glycan bNAbs were studied (Bonsignori et al., 2016; Garces et al., 2015; Julien et al., 2013; Kong et al., 2013; Mouquet et al., 2012; Pejchal et al., 2011; Trkola et al., 1996; Walker et al., 2011).”
HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
Kovacs, J. M., Nkolola, J. P., Peng, H., Cheung, A., Perry, J., Miller, C. A., Seaman, M. S., Barouch, D. H., & Chen, B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204533109 · Cited by 169
“These antibodies either must bind directly to the carbohydrates or penetrate the glycan shield (30).”
BackgroundChemical Biology Approaches to Designing Defined Carbohydrate Vaccines
Anish, C., Schumann, B., Pereira, C. L., & Seeberger, P. H. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.01.002 · Cited by 167
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Burton, D. R. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00858-w · Cited by 178
“For example, studies have shown that the infectivity of several viruses, including dengue virus, West Nile virus (WNV) and HIV, decays with time and that nAbs can accelerate the rate of this decay 16,17,25 .”
BackgroundInfluentialSelf-citationA brief history of the global effort to develop a preventive HIV vaccine
Esparza, J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.018 · Cited by 192
Synthetically defined glycoprotein vaccines: current status and future directions
Adamo, R., Nilo, A., Castagner, B., Boutureira, O., Berti, F., & Bernardes, G. J. L. (2013) · Chemical Science · doi:10.1039/c3sc50862e · Cited by 158
Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer
Mao, Y., Wang, L., Gu, C., Herschhorn, A., Xiang, S.-H., Haim, H., Yang, X., & Sodroski, J. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2351 · Cited by 188
“The SOSIP soluble gp140 structure has been analyzed in two studies 17,54 .”
InfluentialKlein, F., Gaebler, C., Mouquet, H., Sather, D. N., Lehmann, C., Scheid, J. F., Kraft, Z., Liu, Y., Pietzsch, J., Hurley, A., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120423 · Cited by 179
Self-citationTools to therapeutically harness the human antibody response
Wilson, P. C., & Andrews, S. F. (2012) · Nature Reviews Immunology · doi:10.1038/nri3285 · Cited by 147
“By using binding to the HIV spike as the only selection criterion, Scheid et al. and Mouquet et al.”
MethodTas, J. M. J., Koo, J., Lin, Y., Xie, Z., Steichen, J. M., Jackson, A. M., Hauser, B. M., Wang, X., Cottrell, C. A., Torres, J. L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.020 · Cited by 156
“Administering PGT128, which overlaps with the mature BG18 epitope, prevented BG18 gH B cells from participating in the GC (Figures 4G and 4H).”
InfluentialSelf-citationAntibody recognition of carbohydrate epitopes
Haji‐Ghassemi, O., Blackler, R. J., Young, N. M., & Evans, S. V. (2015) · Glycobiology · doi:10.1093/glycob/cwv037 · Cited by 168
“The buried surface areas of the various HIV-1-specific antibodies have been reviewed elsewhere (Kong et al. 2014).”
BackgroundInfluentialBispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2016) · Cell · doi:10.1016/j.cell.2016.04.050 · Cited by 154
Sok, D., Pauthner, M. G., Briney, B. S., Lee, J. H., Saye-Francisco, K. L., Hsueh, J., Ramos, A. G., Le, K. M., Jones, M., Jardine, J. G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.026 · Cited by 151
“Meanwhile, for neutralization of PGT128 against isolates 92BR020 and JR-CSF, we now show that pairwise mutation of the N301 glycan site with G324A, D325A, or H330A substitutions results in complete loss of neutralization (Figure S1C, Table S5).”
BackgroundInfluentialSelf-citationStructural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1
Kong, L., Giang, E., Robbins, J. B., Stanfield, R. L., Burton, D. R., Wilson, I. A., & Law, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202924109 · Cited by 153
Self-citationStructure and Immune Recognition of the HIV Glycan Shield
Crispin, M., Ward, A. B., & Wilson, I. A. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-060414-034156 · Cited by 148
“This complementary approach has been used to assess a growing number of candidate immunogens and to assess the impact of further protein engineering strategies (31, 103, 115, 134, 135, 150).”
BackgroundInfluentialSelf-citationIg-VAE: Generative modeling of protein structure by direct 3D coordinate generation
Eguchi, R. R., Choe, C. A., & Huang, P.-S. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010271 · Cited by 141
“Over the past two decades, the field of protein design has made steady progress, with new computational methods providing novel solutions to challenging problems such as enzyme catalysis, viral inhibition, de novo structure generation and more[1, 2, 3, 4, 5, 6, 7, 8, 9].”
BackgroundSelf-citationIg-VAE: Generative Modeling of Protein Structure by Direct 3D Coordinate Generation
Eguchi, R. R., Choe, C. A., & Huang, P.-S. (2020) · doi:10.1101/2020.08.07.242347 · Cited by 141
Self-citationNeutralizing antibodies to HIV-1 induced by immunization
McCoy, L. E., & Weiss, R. A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121827 · Cited by 155
“, 2011) and interact with the glycan shield of HIV, with potency potentially arising as a result of Env cross-linking by these mAbs (Pejchal et al., 2011).”
BackgroundKepler, T. B., Liao, H., Alam, S. M., Bhaskarabhatla, R., Zhang, R., Yandava, C., Stewart, S. M., Anasti, K. M., Kelsoe, G. H., Parks, R., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.08.006 · Cited by 140
HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant
Simonich, C. A. L., Williams, K. L., Verkerke, H., Williams, J. A., Nduati, R. W., Lee, K. K., & Overbaugh, J. M. (2016) · Cell · doi:10.1016/j.cell.2016.05.055 · Cited by 140
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer
Jahan, S. T., Sadat, S. M. A., Walliser, M., & Haddadi, A. (2017) · Journal of Drug Delivery · doi:10.1155/2017/9090325 · Cited by 153
“Conventional therapies are rapidly eliminated from the body and suffer from widespread distribution into nontargeted organs and tissues [10], whereas targeted therapeutic NPs have gained promising attention through offering a “therapeutic strategy” to tackle the requirements for frequent drug administration, higher do…”
BackgroundRestriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
Schommers, P., Gruell, H., Abernathy, M. E., Tran, M.-K., Dingens, A. S., Gristick, H. B., Barnes, C. O., Schoofs, T., Schlotz, M., Vanshylla, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.010 · Cited by 142
“As expected, removal of potential N-linked glycosylation sites (PNGSs) in the V2 (N160gp120) and V3 (N301gp120, N332gp120) loops mediated resistance to the V1/V2directedbNAbsPG16andPDGM1400and theV3-directedbNAbs 10-1074 and PGT128, respectively (Mouquet et al., 2012; Pejchal et al., 2011; Sok et al., 2014; Walker et…”
Self-citationThe Development of CD4 Binding Site Antibodies during HIV-1 Infection
Lynch, R. M., Tran, L. M., Louder, M. K., Schmidt, S. D., Cohen, M. S., DerSimonian, R., Euler, Z., Gray, E. S., Karim, S. S. A., Kirchherr, J., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00734-12 · Cited by 139
“These epitopes include the membrane-proximal region (MPER) of gp41 (6, 23, 24) and several regions on gp120, including glycan-containing regions at the base of variable regions 1 and 2 (V1V2) (3, 19, 36) and the base of V3 (25, 35) and an epitope within the CD4 binding site (CD4bs) of gp120 (9, 29, 41, 44).”
BackgroundStructural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers
Pritchard, L. K., Vasiljević, S., Ozorowski, G., Seabright, G. E., Cupo, A., Ringe, R. P., Kim, H. J., Sanders, R. W., Doores, K. J., Burton, D. R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.017 · Cited by 140
“Indeed, many potent bNAbs are glycan reactive (Blattner et al., 2014; Falkowska et al., 2014; Garces et al., 2014; Huang et al., 2014; Kong et al., 2013; McLellan et al., 2011; Mouquet et al., 2012; Pancera et al., 2013; Pejchal et al., 2011; Sanders et al., 2002; Scanlan et al., 2002; Scharf et al., 2014; Walker et a…”
InfluentialSelf-citationBroadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env
Scharf, L., Wang, H., Gao, H., Chen, S., McDowall, A. W., & Bjorkman, P. J. (2015) · Cell · doi:10.1016/j.cell.2015.08.035 · Cited by 132
“Rather than penetrating the glycan shield of HIV-1 Envwith only a single loop, a strategy employed by Abs such as PG9 and PGT128 (McLellan et al., 2011; Pejchal et al., 2011), 8ANC195 inserts its entire variable region into a gap in the Env trimer glycan shield at the interface of gp120 and gp41.”
BackgroundThe HIV glycan shield as a target for broadly neutralizing antibodies
Doores, K. J. (2015) · FEBS Journal · doi:10.1111/febs.13530 · Cited by 152
Self-citationMacLeod, D. T., Choi, N. M., Briney, B. S., Garcés, F., Ver, L. S., Landais, E., Murrell, B., Wrin, T., Kilembe, W., Liang, C. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.016 · Cited by 139
“We compared the structural features of PCDN-27A against the other N332-targeting bnAbs for which crystal structures have been solved (Garces et al., 2014; Kong et al., 2013; Pejchal et al., 2011).”
Self-citationHIV broadly neutralizing antibody targets
Wibmer, C. K., Moore, P. L., & Morris, L. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000153 · Cited by 147
“Antibodies targeting V3 show a similar mechanism to V2 site recognition, in that they access a minimal eight residue peptide epitope between positions 323 and 330 via long (20–26 amino acids) CDR-H3s [31].”
BackgroundStamatatos, L., Pancera, M., & McGuire, A. T. (2017) · Immunological Reviews · doi:10.1111/imr.12483 · Cited by 134
Metadata
- Authors
- Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C.-H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- University of Washington (US)
- University of Oxford (GB)
- Cornell University (US)
- Progenics Pharmaceuticals (United States) (US)
- National Institutes of Health (US)
- Imperial College London (GB)
- Japan Science and Technology Agency (JP)
- Corresponding author
- Pejchal, Robert
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Burton, Dennis R.
- Wilson, Ian A.
- ORCID
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Wang, Sheng-Kai
- Stanfield, Robyn L.
- Julien, Jean-Philippe
- Crispin, Max
- Depetris, Rafael
- Cupo, Albert
- Liu, Yan
- McBride, Ryan
- Ito, Yukishige
- Sanders, Rogier W.
- Paulson, James C.
- Feizi, Ten
- Wong, Chi-Huey
- Moore, John P.
- Olson, William C.
- Ward, Andrew B.
- Poignard, Pascal
- Schief, William R.
- Burton, Dennis R.
- Wilson, Ian A.
- Venue
- Science
- Published
- 2011-11-25
- Volume
- 334
- Issue
- 6059
- Pages
- 1097-1103
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3280215
- OpenAlex
- W2128579789
- Cited by
- 694
- References
- 75
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 18 · 2023: 19 · 2022: 25 · 2021: 35 · 2020: 34 · 2019: 37 · 2018: 54 · 2017: 54 · 2016: 62 · 2015: 70 · 2014: 69 · 2013: 105 · 2012: 72
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Canadian Institutes of Health Research (HFE-224662)
- Engineering and Physical Sciences Research Council (EP/G037604/1, GR/S79268/02)
- National Cancer Institute (Y1-CO-1020, U01CA128416)
- National Institute of General Medical Sciences (Y1-GM-1104)
- National Institute of Allergy and Infectious Diseases (AI-33292, F32AI074372, AI74372, R37AI033292, R56AI084817, P01AI082362, AI082362, R01AI033292, R01AI084817, AI84817)
- National Center for Research Resources (P41RR001209, RR017573, P41RR017573)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1, broadly neutralizing antibodies, gp120, glycan shield, V3 loop, antibody penetration
- MeSH terms
- Antibody Specificity, Epitopes, Binding Sites, Antibody, Carbohydrate Conformation, Cell Line, Disaccharides, Glycosylation, Humans, Hydrogen Bonding, Immunoglobulin Fab Fragments, Mannose, Mannosides, Models, Molecular, Mutation, Oligosaccharides, Polysaccharides, Protein Conformation, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, Protein Structure, Tertiary, Crystallography, X-Ray, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.